2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

719 To transplant or not transplant: new insight on the dilemma of post-remission therapy in elderly AML patients treated with venetoclax and azacitidine

Agomoni Saha, Andriy Derkach, PhD2, Baher Krayem, MD3, Ali Kamali, PhD4, Kuo-Kai Chin, M.D.5, Gregory Goldgof, MD, PHD, MS6, Eytan M Stein I, MD7, Roni Tamari, MD8, Xin Wang, MD, MSCE9
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction: Over the past decade, venetoclax/azacitidine (VEN/AZA) has become the standard of care for older adults with newly diagnosed acute myeloid leukemia (AML). The optimal post-remission therapy for elderly patients (pts) who achieve measurable residual disease (MRD)-negativity with VEN/AZA frontline therapy is unknown. In particular, the survival benefit from allogeneic hematopoietic stem cell transplant (HSCT) might be mitigated by the competing risk of transplant-related morbidity and mortality in a subgroup with favorable long-term outcomes with VEN/AZA alone (Pratz, KW, et al. J Clin Oncol. 2022). In the absence of prospective data, in this study, we aim to examine the outcome differences among elderly pts who achieve early MRD- complete remission (CR) with VEN/AZA and underwent consolidation with either HSCT or ongoing maintenance and explore the factors that modify treatment effect.  

Methods: Pts ≥65 years of age with new AML who received VEN/HMA frontline therapy at Memorial Sloan Kettering Cancer Center from 2018-2025 and achieved MRD-CR by flow cytometry by the end of cycle 2 were included. Hematologic Multimodal Analytics Platform (HeMAP), a large language model pipeline, was used to assist electronic health record data extraction with outputs validated by attending hematologists and pathologists (Kamali, A. HemaSphere. EHA2026). Fitness was defined as post remission LVEF >40%; CrCl ≥50; AST/ALT <5xULN; t.bili <2xULN; no symptomatic cardiac disease, O2 supplementation or uncontrolled infections; or per treating physicians’ discretion. OS was defined as time from remission to death. Survival outcomes were compared using Kaplan-Meier estimates and Cox regression with inverse probability weighting to balance age, comorbidity and molecular features. Cumulative incidence of relapse was compared using Gray’s test. Incidence of severe complications within the first-year post-remission, defined as ICU admission, bacteremia or invasive fungal infection, was estimated using cumulative incidence function considering death as a competing event.  

Results: A total of 72 pts were identified (30 HSCT, 23 fit no HSCT (no-HSCT) for primary analyses; 19 unfit). This early MRD- CR cohort was enriched with pts with ELN2024 favorable risk disease (HSCT 87% vs. no-HSCT 75%) with high prevalence of NPM1 (20% vs. 21%) and IDH2 mutations (30% vs. 12%). Compared to no-HSCT pts, HSCT pts were younger (median age 72 vs. 76.5), but otherwise had similar distribution of ECOG, HCT-CI, AML subtype, and baseline molecular features.  

At median follow-up of 41 months (mo) (HSCT 41, no-HSCT 37), HSCT was associated with superior OS compared to no-HSCT (median OS not reached (NR) vs. 19.4mo; 2-year OS 96.1% (89.0-100) vs. 41.2% (24.4-69.6)), even after balancing measured confounders (adjusted hazard ratio (aHR) 0.08 (0.02-0.28)). A landmark analysis at 2.6mo (median remission-HSCT time) showed consistent results (median OS NR vs. 34.2mo; HR 0.18 (0.04-0.79)). In exploratory analyses, unfit pts had comparable OS relative to non-HSCT (median OS 25.5mo vs. 19.4mo; aHR 0.85 (0.41-1.76)). The OS benefit was maintained in pts harboring NPM1 or IDH2 mutations (median OS NR vs. 20.9mo; 2-year OS 100% vs. 43.4% (16.0-67.5); aHR 2.50e-18, p<0.001 (unable to calculate confidence interval); unfit pts included in reference group given sample size constraints).   

The marked OS difference appeared to be driven by significantly lower relapse risk in HSCT group, with a 2-year cumulative incidence of relapse (CIR) being as low as 3.9% (3.0-16.4) compared to 44.5% (22.4-64.5) in non-HSCT group (adjusted subHR 0.09 (0.01-0.65)). Severe complications were more common in HSCT group. At least one incident occurred in 50% vs. 12.5% in HSCT and non-HSCT pts during the first year post-remission, respectively, with a 1-year cumulative risk ratio of 2.22. HSCT pts had more unplanned admissions compared to non-HSCT (median days-alive-and-out-of-hospital at 6-mo: 150 vs. 180, p<0.001; 1-year 332.5 vs. 363, p<0.001).   

Conclusions: Despite higher incidence of complications, HSCT continues to derive marked survival benefit in elderly pts who achieve early MRD- CR with VEN/AZA frontline therapy. HSCT should be considered even in the molecular subgroups that are predicted to have favorable long-term outcomes with VEN/AZA alone. With a more favorable toxicity profile compared to conventional chemotherapy, VEN/AZA may help bridge more elderly pts to HSCT successfully.  

Agomoni Saha: No relevant conflicts of interest to declare.